Abelacimab, formerly known as MAA868, represents a novel approach to managing thrombosis. This antithrombotic agent is a targeted monoclonal protein that blocks the integrin αIIbβ3, a essential player in platelet https://aronnzjt719675.pointblog.net/abelacimab-maa868-a-deep-investigation-into-the-new-thrombosis-treatment-92253375